Drugs / Certoparin
last change Jul 2014 re-read 2 minutes ago

Certoparin

Other / unclassified

Developed for
venous thromboembolism · persistent atrial fibrillation
Investigated by
Novartis · Novartis Pharmaceuticals · University Medicine Greifswald

Trials 6 · a red edge is where a trial was stopped

2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT01660295 Dec 2011 → Jun 2012 impaired renal function disease Novartis Pharmaceuticals Completed No outcome recorded
Phase 34 trials
Phase 3 NCT01179620 Nov 2010 → Mar 2011 Novartis Completed No outcome recorded
Phase 3 NCT00451412 Jan 2007 → Jun 2009 venous thromboembolism Novartis Completed No outcome recorded
Phase 3 NCT00311753 Feb 2006 → Dec 2007 venous thromboembolism Novartis Pharmaceuticals Completed No outcome recorded
Phase 3 NCT00171769 Apr 2005 → Aug 2006 persistent atrial fibrillation Novartis Completed No outcome recorded
Phase 41 trial
Phase 4 NCT00196417 Jan 2003 → Nov 2005 heparin-induced thrombocytopenia University Medicine Greifswald Unknown No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT01164046 Comparator Aug 2010 → Jul 2014 neoplasm, venous thromboembolism University Medical Center Groningen Terminated No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as Certoparin certoparinNCT01164046
6

NCT01660295

NCT01179620

NCT00311753

NCT00196417

NCT00171769

NCT00451412

Modality Other / unclassified “low-molecular-weight heparin certoparin” NCT00171769
Route Subcutaneous Subcutaneously Injected Certoparin” NCT00171769